• Liproxstatin-1: Potent Ferroptosis Inhibitor with IC50 22 nM

  2026-02-15

  Liproxstatin-1 is a potent ferroptosis inhibitor, showing an IC50 of 22 nM in cellular assays. It effectively blocks lipid peroxidation in GPX4-deficient models and protects against iron-dependent cell death. This article validates its benchmarks, outlines mechanistic detail, and clarifies optimal research use.

• Toremifene: Second-Generation SERM for Prostate Cancer Re...

  2026-02-14

  Toremifene stands out as a second-generation selective estrogen-receptor modulator (SERM), enabling robust investigation of hormone-responsive pathways in prostate cancer research. By facilitating detailed in vitro and in vivo studies—including the emerging STIM1-TSPAN18 axis—Toremifene from APExBIO empowers researchers to dissect metastatic mechanisms and optimize experimental reliability.

• 17-AAG (Tanespimycin): Applied HSP90 Inhibition in Oncolo...

  2026-02-13

  17-AAG (Tanespimycin) empowers researchers with a robust, clinically relevant tool for targeted HSP90 inhibition, offering precise degradation of oncogenic proteins and apoptosis induction in diverse cancer models. This guide delivers actionable workflows, troubleshooting tactics, and advanced use-case insights to maximize reproducibility and translational value when deploying this synthetic geldanamycin analogue.

• Toremifene Citrate: Selective Estrogen Receptor Modulator...

  2026-02-13

  Toremifene Citrate is a potent oral selective estrogen receptor modulator (SERM) essential in breast cancer research and estrogen receptor signaling studies. Its competitive antagonism at ERα and ERβ, well-characterized pharmacokinetics, and established in vitro/in vivo benchmarks make it a gold standard for hormone receptor modulation workflows.

• Gefitinib (ZD1839) in the Era of Patient-Derived Assemblo...

  2026-02-12

  This thought-leadership article charts a new course for translational cancer researchers by exploring how Gefitinib (ZD1839) is redefining EGFR pathway inhibition within cutting-edge, patient-derived assembloid models. Integrating mechanistic insights, recent experimental advances, and strategic guidance, we demonstrate how leveraging APExBIO's Gefitinib enables researchers to overcome microenvironment-driven resistance and accelerate the path toward personalized oncology.

• Afatinib in Cancer Biology: Advanced Assembloid Model App...

  2026-02-12

  Afatinib, an irreversible ErbB family tyrosine kinase inhibitor, is transforming cancer biology research by enabling precision dissection of EGFR, HER2, and HER4 signaling in complex tumor microenvironments. Discover how its application in patient-derived assembloid systems drives robust modeling of resistance and optimizes targeted therapy strategies.

• Tunicamycin (SKU B7417): Scenario-Driven Solutions for ER...

  2026-02-11

  This authoritative, scenario-based guide addresses common laboratory challenges in ER stress, cell viability, and inflammation assays, demonstrating how Tunicamycin (SKU B7417) delivers reproducible, data-backed solutions. Through five Q&A blocks rooted in real experimental workflows, we illustrate the unique reliability and scientific value of Tunicamycin for biomedical researchers and lab technicians.

• Prochlorperazine: Advanced Workflows in Melanoma and Anti...

  2026-02-11

  Prochlorperazine, a phenothiazine derivative and potent dopamine D2 receptor antagonist, is transforming both cancer and antiviral research with its multi-targeted mechanisms. Explore stepwise protocols, troubleshooting strategies, and advanced applications that leverage APExBIO’s Prochlorperazine for reproducible, high-impact results across oncology and virology labs.

• Tunicamycin: Gold-Standard Protein N-Glycosylation Inhibi...

  2026-02-10

  Tunicamycin from APExBIO stands out as the definitive protein N-glycosylation inhibitor for dissecting endoplasmic reticulum stress and inflammation suppression in macrophages. This article delivers a bench-to-publication roadmap—complete with optimized protocols, real-world troubleshooting, and advanced applications—empowering researchers to unlock the full translational potential of Tunicamycin in ER stress and glycosylation pathway studies.

• nor-Binaltorphimine dihydrochloride: Advancing κ-Opioid R...

  2026-02-10

  nor-Binaltorphimine dihydrochloride (B6269) empowers researchers to dissect κ-opioid receptor signaling pathways with unprecedented specificity, enabling breakthroughs in pain modulation and addiction studies. This guide provides workflow-driven protocols, advanced applications, and troubleshooting strategies to maximize the compound’s impact in opioid receptor pharmacology.

• Translating Mechanistic Precision into Personalized Oncol...

  2026-02-09

  This thought-leadership article explores how translational researchers can harness the mechanistic specificity of Gefitinib (ZD1839)—a selective EGFR tyrosine kinase inhibitor—to elevate preclinical cancer modeling, especially within patient-derived assembloid systems. By integrating recent advances in tumor–stroma co-culture and resistance profiling, we provide actionable insights that move beyond conventional product literature, offering a strategic framework for optimizing translational workflows and accelerating the next era of personalized cancer therapy.

• Toremifene Citrate: Selective Estrogen Receptor Modulator...

  2026-02-09

  Toremifene Citrate is a highly characterized oral selective estrogen receptor modulator (SERM) widely used in breast cancer research. This article provides atomic, evidence-based insights into its mechanism, receptor binding profile, and pivotal role in modulating estrogen receptor signaling in cancer models.

• 17-AAG (Tanespimycin): Potent Synthetic HSP90 Inhibitor f...

  2026-02-08

  17-AAG (Tanespimycin) is a synthetic geldanamycin analogue and HSP90 inhibitor with nanomolar potency in diverse cancer cell lines. Its well-defined mechanism and favorable solubility profile make it a preferred tool for research on chaperone inhibition, apoptosis induction, and targeted oncogenic pathway disruption.

• Toremifene Citrate: Advanced Insights into SERM Mechanism...

  2026-02-07

  Explore the multifaceted SERM mechanism of action of Toremifene Citrate, an oral selective estrogen receptor modulator vital for breast cancer and endocrinology research. This article delivers an in-depth, mechanistic perspective on receptor signaling, pharmacokinetics, and advanced laboratory applications beyond common protocols.

• Mubritinib (TAK 165): Optimizing HER2 Inhibitor Workflows...

  2026-02-06

  Mubritinib (TAK 165) stands out as a highly selective HER2/ErbB2 inhibitor for dissecting HER2-driven cancer biology and targeted therapy research. Its dual action—HER2 pathway inhibition and mitochondrial targeting—enables robust, reproducible apoptosis assays and mechanistic studies in HER2-positive cancer models.

15787 records 1/1053 page Next 12345 下5页 Last page